With a Senate vote looming and reports of an impending White House proposal, this article discusses what has transpired in ...
Health Affairs' Rob Lott interviews Tiffany Lemon of Arizona State University on her recent paper exploring the concept of ...
In late 2024, the Centers for Medicare and Medicaid Services previewed a significant revision to the risk-adjustment model ...
As policy makers pursue price transparency, they should consider what additional measures could serve as a complement to ...
In this piece, we explore reasons for creating a separate conversion factor within the MPFS, initially for advanced primary ...
We aim to provide transparency in how Elevance Health plans address variations in clinical practices to ensure safe, ...
When the sole manufacturer withdrew a critical cancer drug from Medicare and Medicaid, patients were left without options.
The majority of promotional expenditures are invested in drug samples, one of the industry’s most important marketing tactics ...
In late August 2025, CMS released Performance Year (PY) 2024 data for the Medicare Shared Savings Program (MSSP). This marked ...
The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...
Jessica Bylander ( [email protected]) is a senior editor at Health Affairs, in Bethesda, Maryland. She is reporting this series during a yearlong Reporting Fellowship on Health Care Performance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback